Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.252NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.223NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.223NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.640.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.640.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.5NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.177.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.11 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.11 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.36.12NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.36.12NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.21NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.177.21NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.122.2 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.122.2 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.79 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.79 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AQ.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AQ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BL.1.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BL.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BS.1.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BS.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.7.13.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BF.7.13.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DC.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
DC.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.7.9NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BF.7.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CP.1.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
CP.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.160.8NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.160.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBB.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BE.4.1.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BE.4.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.12NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.177.12NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.41NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.5.2.41NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.6NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BN.1.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CA.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
CA.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.5NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BN.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BE.8NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BE.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.7.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used